Oncotarget is not a just a medical journal for many, but it is a reference guide for research for students and researchers, trusted information on medical procedures for physicians, and a ray of hope for cancer patients around the world. Interestingly, the journal is working as a link between cancer researchers and doctors around the world to share their knowledge and to communicate each other. The weekly medical journal accepts submission from anyone who is doing research in oncology, and it completes a peer review before publishing the work. The editorial board of Oncotarget is a team of highly-qualified experts in oncology from around the world with Andrei V. Gudkov and Mikhail V. Blagosklonny from Roswell Park Cancer Institute, New York as the Editors-in-Chiefs. Follow Oncotarget on Twitter.
The journal started its publication from 2010, and it grown as one the major journals in the coming years with quality works and easy accessibility. From the year it founded, the journal almost tripled every year in the case of total cites, and by the year 2015-16, it crossed more than 10,000. Interestingly, by the year 2015, Oncotarget is the top journal considering the total number of documents with over 3,500 in numbers. The editorial board of the journal is very particular about the accessibility of the journal to everyone and integrated the journal platform with the latest technology. The journal has no printed version and only issues an online version, which users print if needed. The editorial board also thinks that the information should be rapidly and widely available to the people beyond the borders.
The mission of Oncotarget is “life without any diseases, ” and tries put its fingerprints on the long journey. Both Andrei V. Gudkov and Mikhail V. Blagosklonny have decades of experience in cancer research and publishing the results in various journals. Especially, Dr. Blagosklonny has authored more than 200 articles in various peer-reviewed journals until date, and this experience ensures the highest quality articles from Oncotarget. In 2015-16, the journal has received an Impact Factor of 5.008 by the evaluation done by Thomson Reuters JCR. Oncotarget also accepts papers in Metabolism, Cardiology, Neuroscience, Cell Biology, Endocrinology, Pharmacology, and more, apart from oncology.